Dr Barbara Pistilli discusses the case of Marie T., a patient with pretreated HR+/HER2- (IHC 0) metastatic breast cancer (mBC) who has developed endocrine resistance.

 

The key question: What are the next therapeutic options for patients like Marie T.? 

 

In this case-based video, we follow Marie T.’s clinical journey—from diagnosis and treatment to managing adverse events (AEs).  

 

In this video, Dr Pistilli explores: 

  • The mechanism of action of antibody–drug conjugates (ADCs) 
  • Currently available ADCs for HR+/HER2- mBC
  • Strategies for managing ADC-associated AEs 

 

Clinical takeaways

  • Endocrine-resistant HR+/HER2− mBC remains a significant unmet need, and ADCs offer a more effective and tolerable later-line alternative to conventional chemotherapy.
  • Dato-DXd demonstrated a statistically significant and clinically meaningful improvement in PFS versus chemotherapy, with continued benefits across secondary efficacy and PRO endpoints, despite OS not reaching statistical significance—potentially influenced by post-progression ADC use.
  • Sacituzumab govitecan remains a valuable treatment option for heavily pretreated patients with HR+/HER2− breast cancer, demonstrating clinically meaningful improvements in PFS, OS, and PRO, with a manageable safety profile when supported by appropriate care.
  • To support treatment adherence and maintain QoL with ADCs, effective management of AEs is crucial—whether through prophylaxis, supportive medications, interventions, and/or dose modifications.
  • In the absence of predictive biomarkers, selection of ADCs for HR+/HER2− (IHC0) mBC should be guided by prior treatments, clinical characteristics, toxicity profiles, and patient preferences.
  • Recognise the efficacy and safety profiles of TROP2-directed ADCs for patients with advanced or metastatic HR+/HER2- BC, and their place in the treatment landscape
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to monitor and manage adverse events associated with ADC therapy 

Barbara Pistilli, MD is the chair of the breast cancer unit at Gustave Roussy since March 2021. The clinical activity of Breast Cancer Group encloses around 2000 new patients and 700 inclusions in clinical trials, yearly. The goal of the group is to provide groundbreaking and patient-centered strategies that cover all steps from breast cancer prevention to development of innovative treatment strategies and survivorship care. The scientific strategy is driven by the integration between translational and clinical sciences in a limited number of large comprehensive programs, where knowledge in biology drives clinical development and patient samples feed translational research. In this regard, she leads a large translational program focusing on identification of mechanisms of response and resistance to antibody drug conjugates which include a number of phase I and II trials based on diverse treatment strategies in patients with metastatic breast and lung cancer, with a large sample collection for exploratory biomarker analysis.

Dr Barbara Pistilli has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Seagen, Gilead, Novartis, Lilly, MSD, Pierre Fabre, Daiichi Sankyo, Olema and Pfizer

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast

Episode

2

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2

Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer

Experts
Dr Eric Singhi, Dr Isabel Preeshagul, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast

Episode

1

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1

A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC

Experts
Prof. Fernando López-Ríos, MD, PhD, Dr Devika Das, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Survey findings presented at ONS 2025 and published in the journal Healthcare

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning

Module

3

of 3

module
Oncology 
The expanding role of immunotherapy in HCC

Combining locoregional and systemic treatments in intermediate HCC

Experts
Prof. Aiwu Ruth He, Prof. Beau Toskich
Endorsed by
Global Liver Institute ELPA DiCE
Blue Faery
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Apr 2025

AstraZeneca has provided a sponsorship grant towards this independent programme.